首页> 外文期刊>Pharmacogenetics and genomics >Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
【24h】

Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.

机译:MDR1和CYP3A5对成人活体供肝移植患者他克莫司的口服清除率和他克莫司相关的肾功能不全的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVE: The potential influence of the multidrug resistance 1 (MDR1) gene and the cytochrome P450 (CYP) genes, CYP3A4 and CYP3A5, on the oral clearance (CL/F) of tacrolimus in adult living-donor liver transplant patients was examined. Furthermore, the development of renal dysfunction was analyzed in relation to the CYP3A5 genotype. METHODS: Sixty de novo adult liver transplant patients receiving tacrolimus were enrolled in this study. The effects of various covariates (including intestinal and hepatic mRNA levels of MDR1 and CYP3A4, measured in each tissue taken at the time of transplantation, and the CYP3A5*3 polymorphism) on CL/F during the first 50 days after surgery were investigated with the nonlinear mixed-effects modeling program. RESULTS: CL/F increased linearly until postoperative day 14, and thereafter reached a steady state. The initial CL/F immediately after liver transplantation was significantly affected by the intestinal MDR1 mRNA level (P<0.005). Furthermore, patients carrying the CYP3A5*1 allele in the native intestine, but not in the graft liver, showed a 1.47 times higher (95% confidence interval, 1.17-1.77 times, P<0.005) recovery of CL/F with time than patients having the intestinal CYP3A5*3/*3 genotype. The cumulative incidence of renal dysfunction within 1 year after transplantation, evaluated by the Kaplan-Meier method, was significantly associated with the recipient's but not donor's CYP3A5 genotype (*1/*1 and *1/*3 vs. *3/*3: recipient, 17 vs. 46%, P<0.05; donor, 35 vs. 38%, P=0.81). CONCLUSION: These findings suggest that the CYP3A5*1 genotype as well as the MDR1 mRNA level in enterocytes contributes to interindividual variation in the CL/F of tacrolimus in adult recipients early after living-donor liver transplantation. Furthermore, CYP3A5 in the kidney may play a protective role in the development of tacrolimus-related nephrotoxicity.
机译:目的:研究多药耐药性1(MDR1)基因和细胞色素P450(CYP)基因CYP3A4和CYP3A5对他克莫司成人活体供肝移植患者口腔清除率(CL / F)的潜在影响。此外,分析了肾功能不全与CYP3A5基因型的关系。方法:本研究纳入了60例接受他克莫司治疗的新生成人肝移植患者。研究了在手术后的前50天内,各种协变量(包括在移植时在每个组织中测量的MDR1和CYP3A4的肠和肝mRNA水平以及CYP3A5 * 3多态性)对CL / F的影响。非线性混合效应建模程序。结果:CL / F线性增加直至术后第14天,此后达到稳定状态。肝移植后立即的初始CL / F受到肠MDR1 mRNA水平的显着影响(P <0.005)。此外,在患者的天然小肠中但未在移植肝中携带CYP3A5 * 1等位基因的患者,其CL / F随时间的恢复高1.47倍(95%置信区间,1.17-1.77倍,P <0.005)。具有肠道CYP3A5 * 3 / * 3基因型。通过Kaplan-Meier方法评估,移植后1年内肾功能不全的累积发生率与接受者而非供体的CYP3A5基因型显着相关(* 1 / * 1和* 1 / * 3与* 3 / * 3 :受者,17%vs. 46%,P <0.05;供体,35%vs. 38%,P = 0.81)。结论:这些发现提示CYP3A5 * 1基因型以及肠上皮细胞中MDR1 mRNA的水平有助于活体肝移植后成年受体他克莫司CL / F的个体差异。此外,肾脏中的CYP3A5可能在他克莫司相关的肾毒性的发生中起保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号